Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update
November 13, 2019 16:15 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30,...
Altimmune to Announce Third Quarter 2019 Financial Results on November 14
November 06, 2019 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies,...
Altimmune to Participate in Upcoming Investor Conferences
October 10, 2019 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following...
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
September 09, 2019 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief...
Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development
August 21, 2019 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and Development...
Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update
August 13, 2019 16:15 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended...
Altimmune to Announce Second Quarter 2019 Financial Results on August 14
August 05, 2019 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies,...
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
July 15, 2019 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of...
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
July 09, 2019 07:00 ET
|
Altimmune, Inc.
Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH Greater impact on liver fat, inflammation and fibrosis compared...
Altimmune Appoints Will Brown as Chief Financial Officer
June 12, 2019 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial...